Overview

AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. We are developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, our anti-PD-1 agonist program, previously referred to as ANB030, which is currently in a Phase 2 clinical trial for the treatment of moderate-to-severe alopecia areata; and ANB032, our anti-BTLA agonist program. In addition, we are developing imsidolimab, our anti-IL-36R antibody, which is currently in a Phase 3 clinical trial for the treatment of generalized pustular psoriasis, or GPP. We also have additional preclinical programs and discovery research of potentially innovative immunology therapeutics, including ANB033, an anti-CD122 antagonist antibody for the treatment of inflammatory diseases. We have also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI (dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386). We currently generate revenue from milestones and royalties achieved under our immuno-oncology collaboration with GSK. Our antibody pipeline has been developed using our proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies.

Our most advanced wholly owned antibody programs, rosnilimab, ANB032 and imsidolimab, are designed to modulate therapeutic targets that are genetically associated with human inflammatory disorders.

Rosnilimab, our anti-PD-1 agonist antibody program, is designed to suppress aberrant T-cell driven inflammation by augmenting signaling through PD-1 or targeted depletion of PD-1+ T-cells.

Our anti-BTLA modulator antibody, known as ANB032, is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

Imsidolimab is our antibody that inhibits the interleukin-36 receptor for the treatment of inflammatory disease called generalized pustular psoriasis (GPP). We plan to outlicense imsidolimab prior to potential FDA approval.

Our anti-CD122 antagonist antibody program is known as ANB033.

Strategy

Advancing our lead wholly-owned programs for the treatment of severe inflammatory disease

We are developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, our anti-PD-1 agonist program; and ANB032, our anti-BTLA agonist program, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

Continuing imsidolimab development in GPP and outlicensing plans

We are advancing imsidolimab, our anti-IL-36R antibody, for the treatment of generalized pustular psoriasis (GPP), and we are planning to outlicense imsidolimab prior to potential FDA approval.

Identifying emerging target biology opportunities in inflammation and expanding our proprietary pipeline by generating new antibody product candidates using our technology platform

We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation by understanding and translating biological breakthroughs into first-in-class therapeutic antibodies. Our approach includes assessment of human genetics and tissue pathology to understand the relevance of emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to create new product candidates and position our current and future programs for rapid clinical proof-of-concept achievement. Using our proprietary antibody generation platform, we are able to rapidly develop novel therapeutic antibodies against emerging targets. Our goal is to advance multiple additional wholly-owned new therapeutic antibody program to IND submission.

Retaining rights to strategic products in key commercial markets

We intend to retain ownership and control of our pipeline programs to key inflection points. We may build sales and marketing capabilities in selected specialty markets that we believe can be served with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing resources to advance through development and commercialization.

Senior Leadership Team

Angela Stambaugh

Angela Stambaugh

Vice President, Program Management
Ben Stone

Ben Stone

Senior Vice President, Corporate Development
Beth Mueller

Beth Mueller

Senior Vice President, Human Resources
Daniel Faga

Daniel Faga

Interim President & CEO
Dennis Mulroy

Dennis Mulroy

Chief Financial Officer
Eric Loumeau

Eric Loumeau

Chief Operating Officer
Jihao Zhou, MD, Ph.D.

Jihao Zhou, MD, Ph.D.

Vice President, Data Sciences
Kenneth Luu, Ph.D.

Kenneth Luu, Ph.D.

Vice President, Clinical Pharmacology
Lewis Gryziewicz, Ph.D.

Lewis Gryziewicz, Ph.D.

Vice President, Regulatory Affairs
Martin Dahl, Ph.D.

Martin Dahl, Ph.D.

Senior Vice President, Research
Pejman Soroosh, Ph.D.

Pejman Soroosh, Ph.D.

Vice President, Immunology
Priya Raina

Priya Raina

Vice President, Clinical Operations
Stephen Parmley, Ph.D.

Stephen Parmley, Ph.D.

Vice President, Target Biology

Board Of Directors

Daniel Faga

Interim President & CEO

Mr. Faga is a seasoned executive with more than 20 years of industry and advisory experience in the life sciences industry. Most recently, he was the chief operating officer at Mirati Therapeutics responsible for leading the company’s strategy, corporate finance, legal and other business operations.

+

Dennis Fenton, Ph.D.

Former Executive Vice President, Amgen

Dr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President.

+

Laura J. Hamill

Former Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences

Laura J. Hamill joined our Board of Directors in September 2019. Ms. Hamill has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions.

+

Magda Marquet, Ph.D.

Co-founder of Althea Technologies, AltheaDx and ALMA Life Sciences, LLC

Dr. Magda Marquet joined our Board of Directors in January 2021. She was the co-CEO of Althea Technologies from 2000 to 2008. She is currently the co-CEO of Alma Life Sciences. LLC, an investment and consulting firm and serves on several Boards of Directors.

+

Oleg Nodelman

Founder and Portfolio Manager of EcoR1 Capital LLC

Oleg Nodelman joined our Board of Directors in April 2021. He is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, and has nearly twenty years of experience in biotech investing.

+

Hollings Renton

Former President and CEO of Onyx Pharmaceuticals

Hollings Renton has previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals from 1993 to 2008 and as the Chairman of the Board from 2000 to 2008.

+

John Schmid

Former CFO of Auspex Pharmaceuticals

John Schmid has over 35 years of experience in financial and senior management in the biotech industry and has raised over $900 million in private and public equity as well debt financings as a Chief Financial Officer.

+

James N. Topper, M.D., Ph.D.

Chairman of AnaptysBio
Managing General Partner at Frazier Healthcare

Jamie Topper, M.D., Ph.D., is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in the same year. Throughout his 11 years as a General Partner, Dr. Topper has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies.

+

J. Anthony Ware, M.D.

Former SVP Product Development, Lilly Bio-Medicines, Eli Lilly and Company

Dr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas.

+

Scientific Advisory Board

Michael Gallatin, Ph.D.

Former Vice President and Scientific Director of ICOS Corporation

Michael Gallatin, Ph.D., is a former Vice President and Scientific Director of ICOS Corporation, where his responsibilities included discovery, preclinical research, medicinal chemistry and process chemistry groups, including those responsible for worldwide development and launch of Tadalafil (Cialis®).

+

Christopher Hunter, Ph.D.

Mindy Halikman Heyer President’s Distinguished Chair and former chair of the Department of Pathobiology at the University of Pennsylvania School of Veterinary Medicine

Christopher Hunter, Ph.D. is the Mindy Halikman Heyer President’s Distinguished Chair and former chair of the Department of Pathobiology at the University of Pennsylvania School of Veterinary Medicine. Dr. Hunter’s research has focused on the host’s immune response to infections and the innate events that lead to the development of long term protective immunity mediated […]

+

John G. Monroe, Ph.D.

Emeritus Professor, University of Pennsylvania School of Medicine

John G. Monroe, Ph.D., is an Emeritus Professor at the Perelman School of Medicine at the University of Pennsylvania. He is a former Senior Director at Genentech where he led the Immunology Discovery Department that is responsible for new target discovery and pre-clinical validation.

+

Contact

AnaptysBio, Inc.

10770 Wateridge Circle
Suite 210
San Diego, CA 92121-5801

 

Phone: (858) 362-6295
Fax: (858) 362-6296
info@anaptysbio.com

General Information

info@anaptysbio.com

Job Opportunities

Please see our Job Openings page.